230 related articles for article (PubMed ID: 30463536)
1. Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.
Choi W; Li Y; Ji YS; Yoon KC
BMC Ophthalmol; 2018 Nov; 18(1):303. PubMed ID: 30463536
[TBL] [Abstract][Full Text] [Related]
2. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines.
Ujhelyi B; Gogolak P; Erdei A; Nagy V; Balazs E; Rajnavolgyi E; Berta A; Nagy EV
Thyroid; 2012 Apr; 22(4):407-14. PubMed ID: 22385289
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy.
Tsai CC; Kao SC; Cheng CY; Kau HC; Hsu WM; Lee CF; Wei YH
Arch Ophthalmol; 2007 Dec; 125(12):1652-6. PubMed ID: 18071117
[TBL] [Abstract][Full Text] [Related]
5. The tear cytokine profile in patients with active Graves' orbitopathy.
Yang M; Chung Y; Lang S; Yawata N; Seah LL; Looi A
Endocrine; 2018 Feb; 59(2):402-409. PubMed ID: 29147850
[TBL] [Abstract][Full Text] [Related]
6. Measuring urinary 8-hydroxy-2'-deoxyguanosine and malondialdehyde levels in women with overactive bladder.
Dokumacioglu E; Demiray O; Dokumacioglu A; Sahin A; Sen TM; Cankaya S
Investig Clin Urol; 2018 Jul; 59(4):252-256. PubMed ID: 29984340
[TBL] [Abstract][Full Text] [Related]
7. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
8. Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.
Choi W; Lian C; Ying L; Kim GE; You IC; Park SH; Yoon KC
Curr Eye Res; 2016 Sep; 41(9):1143-9. PubMed ID: 26731289
[TBL] [Abstract][Full Text] [Related]
9. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
11. Salivary 8-hydroxy-2-deoxyguanosine, malondialdehyde, vitamin C, and vitamin E in oral pre-cancer and cancer: diagnostic value and free radical mechanism of action.
Kaur J; Politis C; Jacobs R
Clin Oral Investig; 2016 Mar; 20(2):315-9. PubMed ID: 26077895
[TBL] [Abstract][Full Text] [Related]
12. Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves' ophthalmopathy.
Yuksel N; Tanriverdi B; Ipteç B; Erel O
Orbit; 2019 Oct; 38(5):370-375. PubMed ID: 30560705
[No Abstract] [Full Text] [Related]
13. In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.
Cheng S; Yu Y; Chen J; Ye L; Wang X; Jiang F
BMC Ophthalmol; 2021 Jun; 21(1):261. PubMed ID: 34147078
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-7 expression in tears and orbital tissues of patients with Graves' ophthalmopathy.
Cai K; Wei R
Endocrine; 2013 Aug; 44(1):140-4. PubMed ID: 23188693
[TBL] [Abstract][Full Text] [Related]
15. The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients.
Chen Q
J Cell Biochem; 2019 Apr; 120(4):6299-6303. PubMed ID: 30565709
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress in patients with Graves' ophthalmopathy: relationship between oxidative DNA damage and clinical evolution.
Tsai CC; Cheng CY; Liu CY; Kao SC; Kau HC; Hsu WM; Wei YH
Eye (Lond); 2009 Aug; 23(8):1725-30. PubMed ID: 18849914
[TBL] [Abstract][Full Text] [Related]
17. Increased oxidative DNA damage, lipid peroxidation, and reactive oxygen species in cultured orbital fibroblasts from patients with Graves' ophthalmopathy: evidence that oxidative stress has a role in this disorder.
Tsai CC; Wu SB; Cheng CY; Kao SC; Kau HC; Chiou SH; Hsu WM; Wei YH
Eye (Lond); 2010 Sep; 24(9):1520-5. PubMed ID: 20300129
[TBL] [Abstract][Full Text] [Related]
18. The influences of smartphone use on the status of the tear film and ocular surface.
Choi JH; Li Y; Kim SH; Jin R; Kim YH; Choi W; You IC; Yoon KC
PLoS One; 2018; 13(10):e0206541. PubMed ID: 30379901
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Graves' ophthalmopathy patients' tear protein spectrum.
Jiang LH; Wei RL
Chin Med J (Engl); 2013 Dec; 126(23):4493-8. PubMed ID: 24286413
[TBL] [Abstract][Full Text] [Related]
20. Elevated percentage of HLA-DR⁺ and ICAM-1⁺ conjunctival epithelial cells in active Graves' orbitopathy.
Pawlowski P; Mysliwiec J; Mrugacz M; Zak J; Bakunowicz-Lazarczyk A; Rejdak R; Wysocka J; Gorska M
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):641-5. PubMed ID: 24562464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
